Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Scientists at Kowa identify PPARalpha agonists for hyperlipidemia, atherosclerosis, etc.

Jan. 26, 2005

Kyowa Hakko discloses agents for diabetes and related complications

Jan. 26, 2005

New compounds for lipoprotein disorders described in patent literature

Jan. 26, 2005

Taisho scientists prepare and test agents for obesity

Jan. 26, 2005

New compounds for treatment of obesity identified by Novo Nordisk team

Jan. 25, 2005

New agents for type 2 diabetes mellitus covered by Merck patent

Jan. 25, 2005

Bayer presents DGAT-1 inhibitors for obesity and related disorders

Jan. 25, 2005

Update on the pharmacological effects and safety profile of GHRP-2

Jan. 25, 2005

IND acceptance allows initiation of phase I trials of oleoyl estrone

Jan. 25, 2005

Aclasta recommended for approval for Paget's disease in Europe

Jan. 25, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....